[1] While completing his doctorate degree, Stockwell worked in the laboratory of Stuart Schreiber where he spent eighteen months unsuccessfully investigating a molecule that could shut down the protein TGF-beta.
[6] Upon completing his fellowship, Stockwell joined the faculty at Columbia University as an assistant professor of biological sciences and of chemistry.
[3] As a result of his research into undiscovered mechanisms controlling cell death, Stockwell received a 2007 Beckman Young Investigators Award[8] and was named a 2009 Howard Hughes Medical Institute Early Career Scientist.
[3] Following this, he was one of six winners of the BioAccelerate NYC Prize to conduct late-stage, "proof-of-concept" research on a new class of drugs to treat cancer in a more selective and non-toxic way.
[13] During the COVID-19 pandemic, Stockwell co-published Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors through the journal Nature Communications.